-
Kyiv's defences, 'hybrid' threat from Moscow headline EU talks
-
El Nino hammering Peru anchovy fishing: industry officials
-
Oil extends gains, stocks mostly down as Trump issues fresh Iran warning
-
Mass Russian barrage kills 12 in Kyiv
-
ThinkMarkets Expands Weekend Trading Offering, Launches Weekend League Competition
-
PineX Capital Launches MetaTrader 5 as Prop Firm Expands Trading Platform Offering
-
Tibet activists accuse China of downplaying floods
-
Women survivors face sanitation woes in Nepal relief camp
-
Afghanistan war victims left 'without justice', UN says
-
Oil extends gains, stocks mixed as Trump issues fresh Iran warning
-
Iran president offers US olive branch before Putin meeting
-
Thai resort readies for US carrier's 5,000 sailors
-
China-Nepal flood toll tops 1,000 as tunnel rescue offers last hope
-
AI startup Manus says resumes independent operations
-
Japan to relax overtime regulation under workaholic PM
-
'Massive' Russian missile, drone attack on Kyiv kills 8
-
Thwarted Niger mutiny exposes junta's Russia dependence
-
Defence tech hub Munich booms as Europe rearms
-
Illegal mining ravages S.Africa's economic hub
-
Nigeria rethinks criminalisation of suicide
-
Nepal's wall of missing offers last hope after Himalayan flood
-
Osaka channels NBA icon Iverson to reach US Open second round
-
US to press G20 on light-touch AI regulation
-
Fast-fashion giant Shein plunges 10% on Hong Kong debut
-
2 die in Grand Canyon flash flood, only 1 person unaccounted for
-
South Korea hire former Spain boss Moreno as interim coach
-
US Army Secretary Driscoll submits resignation: White House
-
China-Taiwan friction clouds Pacific summit
-
Oil extends gains, stocks drop as Trump issues fresh Iran warning
-
Two dead after stabbing in New York's Times Square
-
Tsitsipas says Kyrgios's positive cocaine test 'kind of expected'
-
Anthropic signs $35B computing deal with startup backed by Nvidia
-
In Japan's mountains, a different way to manage bears
-
Drones in Ithaca: Azov's Odyssey turns Ukraine war into modern myth
-
Middle East war a boon for UAE defence giant with global ambitions
-
Boat builders keep Pakistan's fishing heritage afloat
-
Former gang member found guilty of murdering Tupac Shakur
-
Australia axe Labuschagne for Zimbabwe, South Africa ODI series
-
CRI Merges In Morrison & Smith, Expanding Alabama Footprint
-
Eagle Plains' Partner Xcite Uranium Commences Drill Program at the Lorado Uranium Project, Saskatchewan
-
Connecting Excellence Group PLC Announces Treasury up By 10 BTC to 72.941 & £655,999 Raised
-
Connecting Excellence Group PLC Announces First Acquisition Heads of Terms & Trading Update
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - September 01
-
Top-seeded Zverev opens US Open campaign
-
Heavy rain at Grand Canyon after flood kills 2, dozen missing
-
US regulator, 22 states accuse Amazon of 'manipulating' ad auctions: lawsuit
-
Kushner blames soccer power struggle for World Cup plan collapse
-
TRON Founder Justin Sun Shares Outlook on Bitcoin, Stablecoins and Global Finance at Bitcoin Asia 2026
-
Buoyant Alcaraz shakes off nerves to advance at US Open
-
Tributes to 'eternal' Messi on Argentina retirement
Bausch Health to Announce Second Quarter 2025 Results on July 30
LAVAL, QC / ACCESS Newswire / July 2, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release second quarter 2025 financial results after market close on Wednesday, July 30, 2025. Bausch Health will host a conference call and live webcast at 5:00 p.m. U.S. EDT to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.
Conference Call Details
Date: | Wednesday, July 30, 2025 |
Time: | 5:00 p.m. U.S. EDT |
Webcast: |
A replay of the conference call will be available on the investor relations website.
About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information, visit www.bauschhealth.com and connect with us on LinkedIn.
###
Investor Contact: | Media Contact: |
Garen Sarafian | Katie Savastano |
(877) 281-6642 (toll-free) | (908) 541-3785 |
SOURCE: Bausch Health Companies Inc.
View the original press release on ACCESS Newswire
A.O.Scott--AT